 Consenting Raptiva efalizumab treated patients with moderate to severe chronic plaque psoriasis and meeting the inclusionexclusion criteria specified will be eligible for participation in this study. Subjects will be enrolled from the Raptiva-treated clinical patient pool at the participating Canadian investigator site. 